IDYA News and Press, IDEAYA Biosciences Inc. From 09/03/25

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors PR Newswire Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025 Preclinical profile of IDE892 and mechanistic...

2025-09-02 09:54:47 ET More on IDEAYA Biosciences Ideaya Biosciences: Moving Into ADCs For Solid Tumors Seeking Alpha’s Quant Rating on IDEAYA Biosciences Historical earnings data for IDEAYA Biosciences Financial information for IDEAYA Biosciences ...

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide PR Newswire Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US ...

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2025 ...

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the dis...

2025-08-05 08:43:16 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Ideaya Biosciences: Moving Into ADCs For Solid Tumors

SOPHiA GENETICS SA (SOPH) is expected to report for Q2 2025 Investors Title Company (ITIC) is expected to report for Q2 2025 Safehold Inc. (SAFE) is expected to report $0.39 for Q2 2025 First Guaranty Bancshares Inc. (FGBI) is expected to report $-0.2 for Q2 2025 United Fire Group...

2025-08-05 06:17:04 ET More on IDEAYA Biosciences Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 Seeking Alpha’s Quant Rating on IDEAYA Biosciences Historical earnings data for IDEAYA Biosciences Financial information for IDEAYA ...

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track to report median PFS data by year-end 2...

IDEAYA Biosciences Inc. (IDYA) is expected to report $-0.85 for Q2 2025